Last updated on January 2017

Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma

Brief description of study

The purpose of this study is to evaluate the safety, PK and efficacy of RP6530, a dual PI3K delta/gamma inhibitor in patients with relapsed and refractory T-cell Lymphoma.

Detailed Study Description

Safety: Treatment-Emergent AE; Treatment-Related AE, SAE and Clinical significant AE; Dose Limiting Toxicities (DLT). PK: Peak Plasma Concentration (Cmax), Area under the plasma concentration versus time curve (AUC), Time of Maximum concentration observed (Tmax). Efficacy: Overall Response Rate (ORR), Progression Free Survival (PFS), Overall Survival (OS) and Duration of Response.

Clinical Study Identifier: NCT02567656

Contact Investigators or Research Sites near you

Start Over

Jasmine Zain

City of Hope
Duarte, CA United States
  Connect »

Bradley Haverkos

University of Colorado Cancer Center
Aurora, CO United States
  Connect »

Yasuhiro Oki, MD

MD Anderson Cancer Center
Houston, TX United States
  Connect »